Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider - Wikidata - wikimedia - TriplyDB

Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider

Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider

http://www.wikidata.org/entity/Q28168531

about

Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence Understanding barriers to optimal medication management for those requiring long-term dialysis: rationale and design for an observational study, and a quantitative description of study variables and data.Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study Summary adherence estimates do not portray the true incongruity between drug intake, nurse documentation and physicians' orders Prescribed dietary phosphate restriction and survival among hemodialysis patients.Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months.Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients.Association between higher rates of cardioprotective drug use and survival in patients on dialysis Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND)Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS Geographic variation in HMG-CoA reductase inhibitor use in dialysis patients.Evaluation of adherence to therapy in patients of chronic kidney disease.Selected pharmacokinetic issues in patients with chronic kidney disease.The adequacy of phosphorus binder prescriptions among American hemodialysis patients.Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases Impact of race on cumulative exposure to antihypertensive medications in dialysis Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Exploring the role of renal pharmacists in outpatient dialysis centres: a qualitative study.The use of pharmaceutical care to improve health-related quality of life in hemodialysis patients in Iran.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial.Dialysis Facility Safety: Processes and Opportunities.Guidance to develop individual dose recommendations for patients on chronic hemodialysis.Efficacy of beta-hydroxy-beta-methylbutyrate supplementation in maintenance hemodialysis patients.The impact of depression on fatigue in patients with haemodialysis: a correlational study.Risk of fracture in adults on renal replacement therapy: a Danish national cohort study.Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies.Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.Regimen complexity and prescription adherence in dialysis patients.A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.

P2860

Q26774337-2C1484B3-836E-47DC-A31E-EF30E1091492 Q26830013-4F5D6DF5-69E7-4C88-8F50-3AA3110FE9E8 Q30657472-847D6D92-3BBC-4162-BF57-4A2A7B11BB5C Q34036349-7B05E7D0-254D-40DF-BB02-C9DE3AD119E2 Q34503699-A4E8285C-8325-448E-A7A4-71971EAAD044 Q34858005-70AC2732-841A-41B5-B0F8-DBD5B216B3DD Q35039319-C24BD067-D38E-4628-B550-D61EDCA4C922 Q35070809-5CF9F16E-4CFD-4B64-9871-F25C6DDEBE35 Q35120709-9C3F03D0-3356-4FD5-B1EA-8B5BB5A30B1A Q35812557-0F7E2320-9C2C-4FA1-B918-E935A2677D28 Q35824855-4A332359-D8FA-444C-87A7-B7A5138A6F14 Q35856417-B6C27FFA-3462-4A83-9BA8-F4DFA0336867 Q35876363-0A4D7B57-CDA7-4003-BFAF-0AF37CD8AA6F Q35959075-312C6EEE-EF56-4ECC-96C5-F005530413AD Q36279054-8294785F-C6CE-429E-8BEE-2C41E0369D67 Q36331383-50A034DA-D8E6-40C5-B6BB-B486A2C0C9C7 Q36398179-1755326F-FE2C-41A7-BC19-48772070DF95 Q36684744-3EC91019-25CB-4CDF-B2ED-CD1D70DD8941 Q36716948-BAF5A30B-E0F1-4106-90D4-82CBEC867496 Q36733922-669F9D25-410D-469B-85EA-342D0E0F92C4 Q36764881-17DD1D7B-AF50-4CB1-A2FA-D3288770CB17 Q36843430-52CDF02D-19D7-4D6E-A127-59BE2196CC50 Q37211036-BE7F9F1A-37C4-41D7-8BB2-EE88F56B2D22 Q37280811-0AD4A215-FB70-48E5-86F9-58DA674FCB63 Q37367719-460FB4A0-6C3D-4B67-B25D-A2AB1875D79E Q37551497-15BC6A5F-4ABF-48A4-ACDA-84E9EA4F0E17 Q37622756-DFED9120-0506-4B15-AF8C-71350F5897D0 Q38005909-AD0D9FBE-530E-48FE-BBB0-7B343A3D84A6 Q38070660-5E809458-F1C6-4114-A03E-0D45D6BBD583 Q38222867-33B12B8F-C643-4873-ABFE-DEC3131BB937 Q38435719-24635AAE-08EE-43CE-AC82-E2B6DFA6A690 Q38527612-987E9DDD-1319-470F-8D26-0E51A2CAD87D Q38817612-F474B388-485F-4FAA-8171-D01CAE768A61 Q38853077-E3A4BE94-169F-4FAA-9DD3-C2A4CA2EAD08 Q39023205-EE58B0C6-0960-4B5D-9E40-FA44AF77F8C8 Q39758072-1AA88CDD-F3EC-4449-9C8B-43B5E633439C Q40193776-4F8380B4-043D-44FD-82F1-4C14CD65989F Q42552831-6746A310-C7D3-499A-B6FD-920542CE49EE Q44687612-26A9A4FD-C6FE-4F2E-9B14-55697144AAF1 Q45826429-C3F08C8F-0515-44B1-BB02-EB39B71D04BB

P2860

Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider

http://www.wikidata.org/entity/Q28168531

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Medication prescribing pattern ...... t-for-profit dialysis provider

@ast

Medication prescribing pattern ...... t-for-profit dialysis provider

@en

Medication prescribing pattern ...... t-for-profit dialysis provider

@nl

type

label

Medication prescribing pattern ...... t-for-profit dialysis provider

@ast

Medication prescribing pattern ...... t-for-profit dialysis provider

@en

Medication prescribing pattern ...... t-for-profit dialysis provider

@nl

prefLabel

Medication prescribing pattern ...... t-for-profit dialysis provider

@ast

Medication prescribing pattern ...... t-for-profit dialysis provider

@en

Medication prescribing pattern ...... t-for-profit dialysis provider

@nl

P1433

Q28168531-B9B1A5EA-5196-45EA-B4A9-70DD6F9D938B

P1476

Q28168531-F2309822-4738-4F43-BF7C-16C48DF8A429

P2093

Q28168531-013D53D6-6725-4569-92DB-29F93E735D46

Q28168531-27C725D7-BD36-4620-B9A3-D4F8650C9836

Q28168531-35D9F390-E914-46DF-A3A2-05813373B195

Q28168531-60E5BCAC-E1DF-49BA-9C5D-81A0E676DF01

Q28168531-705314AB-57B6-4C9A-B5EA-18F549B1822D

Q28168531-832D2FAE-E1FB-466E-B7C8-B6C05AAD9FB2

Q28168531-B6BCA046-CB2C-4B37-9636-DDF6224895A6

Q28168531-F2646831-C1A1-4845-B44E-93DA2D0DC8E8

P2860

Q28168531-0FF32021-DCAF-46EC-845B-F85379EE6A38

Q28168531-1521C803-C2C9-42D3-8B5C-584848BE90ED

Q28168531-21D67BCA-4842-42C1-93CB-7F4ACDCDA3A8

Q28168531-7B20A4A6-9306-47D9-8EB9-F9F85917B493

Q28168531-9DDAE597-0631-4E02-BFE2-CA3E47EE34E1

Q28168531-A687BB22-689A-409F-8DD9-7758C4EB2BBC

Q28168531-A7913665-DF55-4920-8523-3234089CE9E9

P304

Q28168531-8C7EBD68-CCDE-4819-A04F-2E84A4B31113

P31

Q28168531-4755A5FF-17E2-4A1D-B9C2-6E047DB7B5DC

P356

Q28168531-6D7CCB17-EAF2-48BC-842A-F31E814C646C

P407

Q28168531-BF25CF31-1D3A-4DF1-AD3E-9D8105694BA9

P433

Q28168531-060EA591-3E6C-44DD-929B-0EF3201ECFD2

P478

Q28168531-6598BC9C-CFF7-4B44-8315-13D205C6B8FA

P577

Q28168531-320BF8C2-C9E7-4CCE-B1C1-884E28D77CFA

P5875

Q28168531-3A966801-16BF-44AB-98BD-0C8C52EB37BF

P698

Q28168531-6DFE759F-1A71-4A3D-AC56-5AA63E84B77C

P921

Q28168531-77AA7D78-CB59-4043-AC45-CF8FBBB4A696

Q28168531-8062DA76-99C4-440C-A729-E9DDC19ED4AF

P356

P1433

Nephrology Dialysis Transplantation

P1476

Medication prescribing pattern ...... t-for-profit dialysis provider

@en

P2093

Cory G Garvin

http://www.w3.org/2001/XMLSchema#string

Debra K Drayer

http://www.w3.org/2001/XMLSchema#string

Gerald M Reid

http://www.w3.org/2001/XMLSchema#string

Harold J Manley

http://www.w3.org/2001/XMLSchema#string

Richard S Muther

http://www.w3.org/2001/XMLSchema#string

Sudarshan Hebbar

http://www.w3.org/2001/XMLSchema#string

Timothy K Neufeld

http://www.w3.org/2001/XMLSchema#string

Walter L Bender

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

The clinical and economic impact of pharmaceutical care in end-stage renal disease patients.

Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center.

Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe.

Factors associated with medication-related problems in ambulatory hemodialysis patients.

Fluoxetine in depressed patients on dialysis.

P304

1842-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFH280

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8576549

http://www.w3.org/2001/XMLSchema#string

P698

15128886

http://www.w3.org/2001/XMLSchema#string

P921